Clinical Trials Logo

Myocardial Ischemia clinical trials

View clinical trials related to Myocardial Ischemia.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06452121 Not yet recruiting - Clinical trials for Coronary Artery Disease

TyG Index as a Marker to Predict Severity of Coronary Artery Disease

Start date: September 1, 2024
Phase:
Study type: Observational

Triglyceride glucose (TyG) index is a novel marker, which has been demonstrated to have a high sensitivity and specificity in identifying metabolic syndrome . Previous studies have shown that TyG index is associated with carotid atherosclerosis, coronary artery calcification and high risk of CVD. This study aims to predict severity of CAD using TyG index and its correlation to coronary angiography findings.

NCT ID: NCT06438393 Not yet recruiting - Clinical trials for Coronary Artery Disease

Screening Coronary Artery Disease Using artiFicial intelligencE in Non-contrast Computed Tomography

SAFE-CT
Start date: June 2024
Phase:
Study type: Observational

This project aims to improve direct patient care by reducing the risks of futile exposure to ionizing radiation and iodinated contrast in patients referred for coronary computed tomography angiography

NCT ID: NCT06425120 Not yet recruiting - Clinical trials for Coronary Heart Disease

Effect of Xuesaitong Soft Capsules on Major Risk Factors in Patients With Coronary Heart Disease

Start date: May 31, 2024
Phase: Phase 4
Study type: Interventional

This trials aims to assess, in 240 eligible patients with coronary heart disease, the effects on level of high-sensitivity C-reactive protein (hsCRP) changes from baseline to 12 weeks of Xuesaitong Soft Capsules.

NCT ID: NCT06421363 Not yet recruiting - Clinical trials for Acute Coronary Syndrome

Continuity of Care Between Primary Care Cardiology and Specialty Services for Patients With Chronic Ischemic Heart Disease

CAPRICI
Start date: June 1, 2024
Phase: Phase 4
Study type: Interventional

1.1. Background Cardiovascular disease (CVD) remains the leading cause of death in our country for over four decades. The pathophysiology of CVD begins with various cardiovascular risk factors (CRFs) and their poor management, leading to subclinical lesions in target organs such as albuminuria or left ventricular hypertrophy, which may evolve into CVD. This progression is referred to as the cardiovascular continuum. Patients with chronic cardiovascular conditions require comprehensive periodic health monitoring in primary care (PC), including lifestyle advice and an assessment of comorbidities. Risk factors linked to disease progression are monitored and managed, along with medication reconciliation and planning follow-up care. Such activities, especially post-COVID, help maintain clinical stability and organize healthcare demand, reducing unnecessary interventions and costs. In Galicia, continuity of care programs for ischemic heart disease focus on optimizing service delivery at appropriate levels, including electronic consultations that improve healthcare accessibility, outcomes, and cost-effectiveness. Introducing Inclisiran for chronic CVD patients post-acute coronary syndrome (ACS) hospitalization might streamline care continuity, reducing healthcare costs and improving outcomes. 1.2. Purpose The disruption of care continuity in patients post-ACS increases their risk of mortality and hospitalizations due to coronary complications and comorbidities, as well as emergency visits and unplanned healthcare interactions, thus elevating healthcare costs. We propose reorganizing care continuity for ACS patients by establishing a PC pathway with scheduled semi-annual visits to assess overall and cardiovascular health and to evaluate patient prognosis and healthcare resource utilization. 2. Objectives 2.1. Primary Objectives The main goal is to evaluate whether a follow-up program incorporating Inclisiran treatment in patients with chronic coronary syndrome can optimize follow-up (reducing unscheduled visits to PC and hospital emergency departments), improve control of risk factors (like physical activity, adherence to a Mediterranean diet, lipid profiles, blood pressure, glycemic profile, and renal function), and decrease direct economic costs. 2.2. Secondary Objectives The secondary objectives include analyzing adherence to prescribed chronic pharmacological treatment, factors driving higher demand among patients with chronic coronary syndrome, reasons for emergency visits, hospital admissions, and causes of mortality among these patients. 3. Methodology 3.1. Study Design A pilot, multicentric, analytical intervention study will be conducted involving five health centers in the Santiago de Compostela health area, with specific inclusion and exclusion criteria outlined. The study will monitor patients over 27 months, following a detailed protocol.

NCT ID: NCT06419894 Not yet recruiting - Clinical trials for Coronary Artery Disease

Advanced Cardiac Magnetic Resonance Imaging for Assessment of Obstructive Coronary Artery Disease: ADVOCATE-CMR

ADVOCATE-CMR
Start date: June 1, 2024
Phase:
Study type: Observational

Stress perfusion cardiovascular magnetic resonance (CMR) imaging is an established non-invasive imaging test for detection of obstructive coronary artery disease (CAD). Fully automated quantitative perfusion CMR (QP CMR) is a new technical advancement, which offers measurement of myocardial blood flow in CMR. Additionally, recent innovations have introduced various contrast-agent-free methods for CAD assessment, such as stress T1 mapping reactivity (∆T1) and oxygen-sensitive CMR (OS CMR). These methods might eliminate the necessity for contrast administration in clinical practice, simplifying, reducing time, invasiveness and costs in evaluating patients with suspected obstructive CAD. The ADVOCATE-CMR study aims to validate QP CMR, ∆T1 and OS CMR imaging against invasive fractional flow reserve (FFR) for detection of obstructive CAD. The study also aims to head-to-head compare the diagnostic accuracy of these CMR techniques with the conventional visual assessment of stress perfusion CMR and to correlate them to short- and long-term clinical outcomes.

NCT ID: NCT06414330 Not yet recruiting - Cardiac Ischemia Clinical Trials

Ringer Acetate Based Modified Del Nido Cardioplegia Solution Versus HTK Solution Cardioplegia Solution in Cardiac Surgery

HTK
Start date: June 1, 2024
Phase: N/A
Study type: Interventional

Low chloride solutions were proved to be better in resuscitation of emergency cases and decrease the resulting hyperchloremic metabolic acidosis in the last decade. In ringers' acetate solutions, there is acetate, which is metabolized in muscles to produce bicarbonate molecules, so neutralizing the ongoing lactic and hyperchloremic metabolic solutions. Both solutions were proved to be superior to normal saline as a fluid therapy plan in most studies with much less ongoing hyperchloremic metabolic acidosis and inflammatory response. In this protocol, modified Del Nido formula will be involved using ringers' acetate instead of plasmalyte solutions and comparing the effects on myocardial protection versus HTK solutions

NCT ID: NCT06404515 Not yet recruiting - Clinical trials for Coronary Artery Disease

Telehealth Group Counseling and Preventive Care for Women

Start date: May 24, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to utilize an innovative healthcare delivery strategy via telehealth group counseling sessions to improve engagement, adherence, and ultimately outcomes in female patients with atherosclerotic cardiovascular disease (ASCVD).

NCT ID: NCT06400290 Not yet recruiting - Stable Angina Clinical Trials

Multivessel Balloon Occlusion to Investigate Obstructive Coronary Artery Disease and aNgina

ORBITA-MOON
Start date: May 2024
Phase: N/A
Study type: Interventional

ORBITA-MOON is a double-blinded, placebo-controlled experimental study that aims to understand how the different coronary artery stenoses contribute to overall clinical angina in patients with multi-vessel coronary artery disease. This study will investigate the symptoms conferred by each stenosis, induced by experimental ischaemia, for 60 patients with multi-vessel coronary artery disease.

NCT ID: NCT06392958 Not yet recruiting - Clinical trials for Coronary Heart Disease

Application of Improved Baduanjin Combined Cross-theoretical Model Based on Internet in Family Empowering Elderly PCI Cardiac Rehabilitation

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

This study explores the effect of Internet based improved Baduanjin combined cross-theoretical model in family empowering cardiac rehabilitation for elderly patients with coronary heart disease after PCI, provides a scientific and reasonable case management plan for the rehabilitation of patients with coronary heart disease, and provides a reference for the development of scientific and refined cardiac rehabilitation case management suitable for elderly patients with PCI.

NCT ID: NCT06387355 Not yet recruiting - Clinical trials for Coronary Artery Disease

Diagnosis and Treatment of CAD in Severe PAD After Lower Extremity Revascularization

CAD in sPAD
Start date: August 1, 2024
Phase: N/A
Study type: Interventional

Peripheral artery disease, lack or blood flow to the legs, has a high prevalence in the Veteran population. In patients with severe peripheral artery disease that requires an endovascular or surgical intervention for lower leg revascularization, the long-term mortality of approximately 50% is worse that most cancers. The goal of this study is to develop a management strategy to improve cardiovascular outcomes in this high-risk peripheral artery disease population after lower extremity revascularization.